All News

Copay Assistance Programs Help Patients but Confuse Them Too

d MedPage Today

"If you're having trouble paying for your medications, Drug Company X may be able to help."

Read Article
podcast logo

RheumNow Podcast – Steroids, IVIG & the Vaccine (1.15.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more...

Read Article
2020 Year Review

2020 Rheumatology Year in Review

d Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
Jo1.gottrons.jpg

ProDERM Study: IVIG in Dermatomyositis

d Jack Cush, MD

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article
lupus.nephritis.immunofluorescence.jpg

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

d Jack Cush, MD

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.

Read Article
Rheumatologists: Record your question or case for the RheumNow podcast. https://t.co/wzNmOzH4VE https://t.co/dgTTvRqESI

Links:

Dr. John Cush RheumNow ( View Tweet)
ProDERM Study: IVIG in Dermatomyositis--The ProDERM study show that IVIg is safe, effective and superior to placebo in patients with dermatomyositis (DM). https://t.co/HOB8CYn9yc https://t.co/AmT3AQdawa

Links:

Dr. John Cush RheumNow ( View Tweet)
Real good historic review of RA drug development wherein Dr Paul Emery interviews Dr. Mike Weinblatt - Good Listen from the Cytokine Signaling Forum podcast https://t.co/R7rg7AwVlG

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Stopping Meds https://t.co/zhtAHLeGqT https://t.co/rFmCch4WJ4

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts. https://t.co/MD6lU5oIvy

Links:

Dr. John Cush RheumNow ( View Tweet)

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis--Takeuchi et al has published their extensive experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy. https://t.co/hgMp5GcyFA https://t.co/Xdxg3v3wMm

Links:

Dr. John Cush RheumNow ( View Tweet)
Good reference Medical Research Council Manual Muscle scale (0-5) 0 No muscle activation 1 Trace muscle movt/twitch 2 Muscle movt w/o gravity 3 Movt against gravity 4 Movt against some resistance 5 Movt against full resistance, full range of motion https://t.co/UVN6oHIL1L

Links:

Dr. John Cush RheumNow ( View Tweet)

Delays in Diagnosis of Axial Spondyloarthritis-Researchers found tht from 64 included studiesl, the mean diagnostic delay in axSpA patients was 6.7 years (95% CI 6.2, 7.2) with high levels of heterogeneity. https://t.co/cOC1R264aC https://t.co/5UC7aip7j0

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Shortage During COVID-19--According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic. https://t.co/h9hrAfv9xo https://t.co/IVSYCueK2h

Links:

Dr. John Cush RheumNow ( View Tweet)
2 yr Early RA cohort (CareRA) study found that RA pPatients with co-morbidities had over time lower chances of achieving remission (OR = 0.724; 95% CI: 0.604, 0.867) and a higher risk of hospitalization (OR = 3.725; 95% CI: 2.136, 6.494).https://t.co/B1um1iMSKu

Links:

Dr. John Cush RheumNow ( View Tweet)

Born to Run (things) - the short inspirational start and career of Bruce Springsteen. https://t.co/Ki86v4viAj

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts. https://t.co/r5Cf4WS63s https://t.co/fEV77xMUye

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats- top presentations in nr-axSpA, AS, axial PsA and Still’s disease. Sponsored by Novartis Medical Affairs Unable to attend the key sessions at #ACR20? Listen to the experts as they weigh in on the top abstracts. https://t.co/oGwmEXNaur https://t.co/S23cZw4Li1

Links:

Dr. John Cush RheumNow ( View Tweet)
Chinese SLE CSTAR study of 4792 SLE patients, of whom 374 (7.8%) had scarring alopecia. Risk factors for scarring alopecia included mucocutaneous lesions (OR 2.1) high SLICC/ACR-DI (OR 1.4), & positive Sm (OR 1.4), but less seen w/ renal CV involvement https://t.co/Y466WK3shS

Links:

Dr. John Cush RheumNow ( View Tweet)

Survey of 428 Rheums in Brazil finds they are prone to promote physical activity; but less than 1/4 had training, 14% dont assess phys activity routinely, & half dont know minimum recommendations. Major gaps in knowledge about physical activity recs exist https://t.co/7WwuR0bqpJ

Links:

Dr. John Cush RheumNow ( View Tweet)

×